Site
Search results (Showing 1 - 10 of 50 results)
-
References | 28 Nov 2015
Physician-patient communication skills: e-tools.
-
References | 14 Feb 2013
[Chronically Ill and Unemployed? A Review on Vocational Status in Multiple Sclerosis].
Kern S, Kühn M, Ziemssen TFortschr Neurol Psychiatr. 2013 Feb; 81(2):95-103. Epub 2013 Feb 14. PMID: 23412961. Abstract -
References | 5 Nov 2015
Pangaea 2.0: State Of The Art Multiple Sclerosis Patient Management In Daily Clinical Practice. A New 3-Year Observational Study Of Patients Receiving Fingolimod.
Ziemssen T, Kern R, Cornelissen CValue Health. 2015 Nov; 18(7):A686. Epub 2015 Oct 20. PMID: 26533847. Abstract -
References | 2 Sep 2016
Immunomodulatory treatments and cognition in MS.
Mückschel M, Beste C, Ziemssen TActa Neurol Scand. 2016 Sep; 134 Suppl 200:55-9. PMID: 27580907. Abstract -
References | 21 Nov 2014
PANGAEA: Post-authorization Noninterventional German Safety Study of GilEnyA in relapsing-remitting multiple sclerosis (RRMS) patients: A 24-month interim analysis of a German five-year fingolimod registry study.
Ziemssen T, Diaz-Lorente M, Abdelkader M, Cornelissen CMult Scler Relat Disord. 2014 Nov; 3(6):751. Epub 2014 Nov 21. PMID: 25891587. Abstract -
References | 8 Oct 2015
Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate.
Ziemssen T, Gilgun-Sherki YBMC Neurol. 2015; 15(1):189. Epub 2015 Oct 08. PMID: 26450155. Abstract -
References | 31 Jul 2013
Neuroborreliosis during natalizumab treatment in multiple sclerosis.
Thomas K, Schultheiss T, Ziemssen TNeurology. 2013 Jul 26. PMID: 23892705. Abstract -
References | 21 Nov 2014
Good cardiac safety in patients with relapsing remitting multiple sclerosis upon first fingolimod dose.
Limmroth V, Hoyer S, Schmidt S, Lang M, Ziemssen TMult Scler Relat Disord. 2014 Nov; 3(6):754. Epub 2014 Nov 21. PMID: 25891594. Abstract -
References | 18 Jun 2015
The PANGAEA study design- a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice.
Ziemssen T, Kern R, Cornelissen CBMC Neurol. 2015; 15:93. Epub 2015 Jun 18. PMID: 26084334. Abstract -
References | 5 Nov 2015
Development of A Screening Tool to Support Identification of Patients With Secondary Progressive Multiple Sclerosis (Spms).
Ziemssen T, Simsek D, Lahoz R, Verdun di Cantogno EValue Health. 2015 Nov; 18(7):A763. Epub 2015 Oct 20. PMID: 26534272. Abstract